<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503540</url>
  </required_header>
  <id_info>
    <org_study_id>15-442</org_study_id>
    <nct_id>NCT02503540</nct_id>
  </id_info>
  <brief_title>Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO</brief_title>
  <acronym>PERMEATE</acronym>
  <official_title>Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Justis Ehlers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This interventional study will evaluate the retinal vascular dynamics associated with&#xD;
      Intravitreal Aflibercept Injection (IAI) therapy in eyes with diabetic macular edema (DME) or&#xD;
      macular edema secondary to retinal vein occlusion (RVO). Ultra-widefield fluorescein&#xD;
      angiography and optical coherence tomography (OCT) angiography will be performed at multiple&#xD;
      timepoints to assess the changes in retinal vascular leakage, ischemia, and vascular&#xD;
      abnormalities throughout the study duration and compare these alterations to baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic macular edema (DME) and macular edema secondary to retinal venous occlusive diseases&#xD;
      are the most common cause of vision loss from a retinal vascular disease. Recently, vascular&#xD;
      endothelial growth factor (VEGF) inhibitors (bevacizumab, aflibercept, and ranibizumab) have&#xD;
      been described as new first-line therapies for these conditions. Aflibercept is the most&#xD;
      recently approved VEGF inhibitor for the management of these conditions. Clinical trials have&#xD;
      shown that treatment with aflibercept improves visual acuity and reduces macular edema in a&#xD;
      large percentage of patients.&#xD;
&#xD;
      This study will examine the changes that occur with intravitreal aflibercept to perfusion and&#xD;
      leakage in treatment naive eyes over the course of 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 18, 2015</start_date>
  <completion_date type="Actual">February 6, 2018</completion_date>
  <primary_completion_date type="Actual">February 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Panretinal Leakage Index at Month 12 From Baseline</measure>
    <time_frame>12 months</time_frame>
    <description>Change in panretinal leakage index (defined as the proportion of retinal area involved in angiographic leakage) at month 12 from baseline as measured by ultra-widefield angiography (UWFA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Total Leakage Index</measure>
    <time_frame>6 months</time_frame>
    <description>Mean change in total leakage index from baseline to month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Panretinal Ischemic Index</measure>
    <time_frame>12 months</time_frame>
    <description>Change in panretinal ischemic index from baseline to postoperative month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Panretinal Ischemic Index From Baseline at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Change in panretinal ischemic index (defined as the proportion of retinal area with nonperfusion) from baseline at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Central Subfield Thickness</measure>
    <time_frame>6 months</time_frame>
    <description>OCT central subfield thickness change from baseline to 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) Score Based on ETDRS</measure>
    <time_frame>12 months</time_frame>
    <description>Mean change from baseline in best-corrected visual acuity (BCVA) score from baseline to month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Gained 15 ETDRS Letters or More of Vision</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Gained 15 ETDRS Letters or More of Vision</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Showed Visual Acuity 20/40 or Better</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Showed Visual Acuity 20/200 or Worse</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Lost 15 ETDRS Letters or More of Vision</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Lost 15 ETDRS Letters or More of Vision</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Showed Visual Acuity 20/40 or Better</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients That Showed Visual Acuity 20/200 or Worse</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline Central Subfield Thickness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Serious Adverse Events</measure>
    <time_frame>12 Months</time_frame>
    <description>Incidence of systemic SAEs</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Retinal Vein Occlusion</condition>
  <condition>Diabetic Macular Edema</condition>
  <condition>Branch Retinal Vein Occlusion</condition>
  <condition>Central Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Aflibercept</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monthly aflibercept for 6 months and then every other month for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
    <arm_group_label>Aflibercept</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        A subject must meet the following criteria to be eligible for inclusion in the study:&#xD;
&#xD;
          1. Signed Informed Consent.&#xD;
&#xD;
          2. Men and women â‰¥ 18 years of age.&#xD;
&#xD;
          3. Foveal-involving retinal edema secondary to DME or RVO based on investigator review of&#xD;
             SDOCT.&#xD;
&#xD;
          4. E-ETDRS best-corrected visual acuity of: 20/25 to 20/400 in the study eye or Hand&#xD;
             Motion (HM) in the study eye.&#xD;
&#xD;
          5. Willing, committed, and able to return for all clinic visits and complete all study&#xD;
             related procedures.&#xD;
&#xD;
          6. Able to read, (or, if unable to read due to visual impairment, be read to verbatim by&#xD;
             the person administering the informed consent or a family member) understand and&#xD;
             willing to sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        A subject who meets any of the following criteria will be excluded from the study:&#xD;
&#xD;
          1. Any prior or concomitant therapy with another investigational agent to treat DME or&#xD;
             RVO in the study eye.&#xD;
&#xD;
          2. Prior panretinal photocoagulation in the study eye.&#xD;
&#xD;
          3. Prior intravitreal anti-VEGF therapy in the study eye.&#xD;
&#xD;
          4. Prior focal/grid laser photocoagulation in the study eye.&#xD;
&#xD;
          5. Prior history of intravitreal steroid therapy in the study eye.&#xD;
&#xD;
          6. Any history of allergy to fluorescein sodium or other reason that the patient is&#xD;
             unable to undergo fluorescein angiography (e.g., inability to get vascular access,&#xD;
             unable to tolerate procedure)&#xD;
&#xD;
          7. Prior systemic anti-VEGF therapy, investigational or FDA-approved, is only allowed up&#xD;
             to 3 months prior to first dose, and will not be allowed during the study.&#xD;
&#xD;
          8. Significant vitreous hemorrhage obscuring view to the macula or the retinal periphery&#xD;
             as determined by the investigator on clinical exam and ultra-widefield angiography.&#xD;
&#xD;
          9. Presence of other causes of macular edema, including myopic degeneration, ocular&#xD;
             histoplasmosis syndrome, angioid streaks, choroidal rupture, choroidal&#xD;
             neovascularization, neovascular age-related macular degeneration or multifocal&#xD;
             choroiditis in the study eye. Epiretinal membranes are allowed.&#xD;
&#xD;
         10. Presence of macula-threatening traction retinal detachment.&#xD;
&#xD;
         11. Prior vitrectomy in the study eye.&#xD;
&#xD;
         12. History of retinal detachment or treatment or surgery for retinal detachment in the&#xD;
             study eye.&#xD;
&#xD;
         13. Any history of macular hole of stage 2 and above in the study eye.&#xD;
&#xD;
         14. Any intraocular or periocular surgery within 3 months of Day 1 on the study eye,&#xD;
             except lid surgery, which may not have taken place within 1 month of day 1, as long as&#xD;
             it's unlikely to interfere with the injection.&#xD;
&#xD;
         15. Prior trabeculectomy or other filtration surgery in the study eye.&#xD;
&#xD;
         16. Uncontrolled glaucoma at baseline evaluation (defined as intraocular pressure â‰¥25 mmHg&#xD;
             despite treatment with anti-glaucoma medication) in the study eye.&#xD;
&#xD;
         17. Active intraocular inflammation in either eye.&#xD;
&#xD;
         18. Active ocular or periocular infection in either eye.&#xD;
&#xD;
         19. Any ocular or periocular infection within the last 2 weeks prior to Screening in&#xD;
             either eye.&#xD;
&#xD;
         20. Any history of uveitis in either eye.&#xD;
&#xD;
         21. Active scleritis or episcleritis in either eye.&#xD;
&#xD;
         22. Presence or history of scleromalacia in either eye.&#xD;
&#xD;
         23. Aphakia in the study eye.&#xD;
&#xD;
         24. Previous therapeutic radiation in the region of the study eye.&#xD;
&#xD;
         25. History of full-thickness penetrating keratoplasty in the study eye. Partial thickness&#xD;
             corneal transplants including Descemet stripping automated endothelial keratoplasty&#xD;
             and Descemet membrane endothelial keratoplasty are allowed.&#xD;
&#xD;
         26. Significant media opacities, including cataract, in the study eye which might&#xD;
             interfere with visual acuity, assessment of safety, or fundus photography.&#xD;
&#xD;
         27. Any concurrent intraocular condition in the study eye (e.g. cataract) that, in the&#xD;
             opinion of the investigator, could require either medical or surgical intervention&#xD;
             during the 52 week study period.&#xD;
&#xD;
         28. Any concurrent ocular condition in the study eye which, in the opinion of the&#xD;
             investigator, could either increase the risk to the subject beyond what is to be&#xD;
             expected from standard procedures of intraocular injection, or which otherwise may&#xD;
             interfere with the injection procedure or with evaluation of efficacy or safety.&#xD;
&#xD;
         29. Participation as a subject in any clinical study within the 12 weeks prior to Day 1.&#xD;
&#xD;
         30. Any systemic therapy with an investigational agent in the past 3 months prior to Day&#xD;
             1.&#xD;
&#xD;
         31. Any history of allergy to povidone iodine.&#xD;
&#xD;
         32. Pregnant or breast-feeding women&#xD;
&#xD;
         33. Women of childbearing potential* who are unwilling to practice adequate contraception&#xD;
             during the study (adequate contraceptive measures include stable use of oral&#xD;
             contraceptives or other prescription pharmaceutical contraceptives for 2 or more&#xD;
             menstrual cycles prior to screening; intrauterine device (IUD); bilateral tubal&#xD;
             ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly, or diaphragm&#xD;
             plus contraceptive sponge, foam, or jelly)&#xD;
&#xD;
               -  Postmenopausal women must be amenorrheic for at least 12 months in order not to&#xD;
                  be considered of child bearing potential. Pregnancy testing and contraception are&#xD;
                  not required for women with documented hysterectomy or tubal ligation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justis P Ehlers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cole Eye Institute, Cleveland Clinic, OH 44195</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cole Eye Institute, Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wessel MM, Nair N, Aaker GD, Ehrlich JR, D'Amico DJ, Kiss S. Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol. 2012 May;96(5):694-8. doi: 10.1136/bjophthalmol-2011-300774. Epub 2012 Mar 15.</citation>
    <PMID>22423055</PMID>
  </reference>
  <reference>
    <citation>Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax. 1999 Aug;54(8):707-10.</citation>
    <PMID>10413724</PMID>
  </reference>
  <reference>
    <citation>Singer M, Tan CS, Bell D, Sadda SR. Area of peripheral retinal nonperfusion and treatment response in branch and central retinal vein occlusion. Retina. 2014 Sep;34(9):1736-42. doi: 10.1097/IAE.0000000000000148.</citation>
    <PMID>24732695</PMID>
  </reference>
  <reference>
    <citation>Rakic JM, Lambert V, Devy L, Luttun A, Carmeliet P, Claes C, Nguyen L, Foidart JM, NoÃ«l A, Munaut C. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003 Jul;44(7):3186-93.</citation>
    <PMID>12824270</PMID>
  </reference>
  <reference>
    <citation>Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res. 2000;55:15-35; discussion 35-6. Review.</citation>
    <PMID>11036931</PMID>
  </reference>
  <reference>
    <citation>Ferrara N, Houck KA, Jakeman LB, Winer J, Leung DW. The vascular endothelial growth factor family of polypeptides. J Cell Biochem. 1991 Nov;47(3):211-8. Review.</citation>
    <PMID>1791185</PMID>
  </reference>
  <reference>
    <citation>Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997 Feb;18(1):4-25. Review.</citation>
    <PMID>9034784</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 17, 2015</study_first_submitted>
  <study_first_submitted_qc>July 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <results_first_submitted>January 29, 2020</results_first_submitted>
  <results_first_submitted_qc>January 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2020</results_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Justis Ehlers</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>macular edema</keyword>
  <keyword>rvo</keyword>
  <keyword>diabetic macular edema</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT02503540/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from within ophthalmology clinics.</recruitment_details>
      <pre_assignment_details>Single arm study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Aflibercept</title>
          <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>Aflibercept</title>
          <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Measure Analysis Population Description: The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.1" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Measure Analysis Population Description: The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>Measure Analysis Population Description: The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline best corrected visual acuity</title>
          <population>The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.3" spread="23.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline central subfield thickness</title>
          <population>The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>Î¼m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="541.2" spread="242.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Panretinal leakage index</title>
          <description>Percentage of area of the visible retina that was leaking</description>
          <population>Measure Analysis Population Description: The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Panretinal ischemic index</title>
          <population>Measure Analysis Population Description: The PERMEATE study included 31 eyes. Two participants did not continue the study past month 3 because of elective study withdrawal (n = 1) and death (n = 1). Thus, 29 participants were included in the analysis.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.5" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of patient with visual acuity of 20/200 or worse</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Panretinal Leakage Index at Month 12 From Baseline</title>
        <description>Change in panretinal leakage index (defined as the proportion of retinal area involved in angiographic leakage) at month 12 from baseline as measured by ultra-widefield angiography (UWFA).</description>
        <time_frame>12 months</time_frame>
        <population>Monthly aflibercept for 6 months and then every other month for 6 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Panretinal Leakage Index at Month 12 From Baseline</title>
          <description>Change in panretinal leakage index (defined as the proportion of retinal area involved in angiographic leakage) at month 12 from baseline as measured by ultra-widefield angiography (UWFA).</description>
          <population>Monthly aflibercept for 6 months and then every other month for 6 months.</population>
          <units>percentage of region of interest in UWFA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.14" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Total Leakage Index</title>
        <description>Mean change in total leakage index from baseline to month 6</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Total Leakage Index</title>
          <description>Mean change in total leakage index from baseline to month 6</description>
          <units>percentage of region of interest in UWFA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Panretinal Ischemic Index</title>
        <description>Change in panretinal ischemic index from baseline to postoperative month 12</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Panretinal Ischemic Index</title>
          <description>Change in panretinal ischemic index from baseline to postoperative month 12</description>
          <units>percentage of region of interest in UWFA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Panretinal Ischemic Index From Baseline at 6 Months</title>
        <description>Change in panretinal ischemic index (defined as the proportion of retinal area with nonperfusion) from baseline at 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Panretinal Ischemic Index From Baseline at 6 Months</title>
          <description>Change in panretinal ischemic index (defined as the proportion of retinal area with nonperfusion) from baseline at 6 months</description>
          <units>percentage of region of interest in UWFA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Central Subfield Thickness</title>
        <description>OCT central subfield thickness change from baseline to 6 months</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline Central Subfield Thickness</title>
          <description>OCT central subfield thickness change from baseline to 6 months</description>
          <units>Î¼m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278.0" spread="251.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) Score Based on ETDRS</title>
        <description>Mean change from baseline in best-corrected visual acuity (BCVA) score from baseline to month 12</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) Score Based on ETDRS</title>
          <description>Mean change from baseline in best-corrected visual acuity (BCVA) score from baseline to month 12</description>
          <units>ETDRS letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Gained 15 ETDRS Letters or More of Vision</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Gained 15 ETDRS Letters or More of Vision</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Gained 15 ETDRS Letters or More of Vision</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Gained 15 ETDRS Letters or More of Vision</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Showed Visual Acuity 20/40 or Better</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Showed Visual Acuity 20/40 or Better</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Showed Visual Acuity 20/200 or Worse</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Showed Visual Acuity 20/200 or Worse</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Serious Adverse Events</title>
        <time_frame>12 months</time_frame>
        <population>All enrolled subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Serious Adverse Events</title>
          <population>All enrolled subjects</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Lost 15 ETDRS Letters or More of Vision</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Lost 15 ETDRS Letters or More of Vision</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Lost 15 ETDRS Letters or More of Vision</title>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Lost 15 ETDRS Letters or More of Vision</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Showed Visual Acuity 20/40 or Better</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Showed Visual Acuity 20/40 or Better</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients That Showed Visual Acuity 20/200 or Worse</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Showed Visual Acuity 20/200 or Worse</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline Central Subfield Thickness</title>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline Central Subfield Thickness</title>
          <units>Î¼m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.3" spread="250.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systemic Serious Adverse Events</title>
        <description>Incidence of systemic SAEs</description>
        <time_frame>12 Months</time_frame>
        <population>All subjects enrolled</population>
        <group_list>
          <group group_id="O1">
            <title>Aflibercept</title>
            <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
          </group>
        </group_list>
        <measure>
          <title>Systemic Serious Adverse Events</title>
          <description>Incidence of systemic SAEs</description>
          <population>All subjects enrolled</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aflibercept</title>
          <description>Monthly aflibercept for 6 months and then every other month for 6 months.&#xD;
Aflibercept: Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Justis P. Ehlers</name_or_title>
      <organization>Cole Eye Institute Cleveland Clinic Foundation</organization>
      <phone>2166360183</phone>
      <email>ehlersj@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

